United States Intratumoral cancer therapies market 2025: Industry Developments, Future Growth, Share & Industry Insights | Bristol Myers Squibb Company, BridgeBio Pharma Inc, Boston Scientific Corporation.

Intratumoral cancer therapies market reached US$ 219.79 million in 2023, with a rise to US$ 246.4 million in 2024, and is expected to reach US$ 630.7 million by 2033, growing at a CAGR of 11.0% during the forecast period 2025-2033.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/intratumoral-cancer-therapies-market?sg

Industry Latest News 2025:

✅ 2025-02-14 - UroGen Pharma acquired certain assets of IconOVir Bio, including oncolytic candidate ICVB-1042 (asset purchase expanding intratumoral/oncolytic pipeline).

✅ 2025-05-22 - Candel Therapeutics announced positive Phase-3 CAN-2409 results (met primary endpoint; improvements in DFS reported).

✅ 2025-09-29 - Candel Therapeutics presented CAN-2409 Phase-3 data at ASTRO 2025 (localized prostate-cancer presentation).

✅ 2025-06-30 - Intensity Therapeutics reported INT230-6 achieved 100% complete responses in preclinical MPNST models (preclinical intratumoral formulation milestone).

✅ 2025-10-30 - INT230-6 clinical results published in eBioMedicine reporting safety, disease-control and survival signals in metastatic/refractory cancers.

✅ 2025-09-29 - Nature Communications paper published: post-resection biodegradable scaffold delivering TLR7/8 agonist (resiquimod) showed sustained local delivery and tumor clearance in preclinical glioblastoma models.

✅ 2025-08-05 - JAIST / collaborators published AUN bacterial consortium work (tumour-resident oncolytic bacteria) demonstrating potent intratumoral, immune-independent tumor eradication in preclinical models.

✅ 2025-08 (reported) - Multiple teams reported sustained-release intratumoral TLR7/8 (resiquimod/TransCon-style) approaches showing enhanced local immune activation in 2025 preclinical/early-clinical reports.

✅ 2025-06 (ASCO 2025 coverage) - Investigator-led intratumoral approaches (e.g., SYNC-T in-situ personalized intratumoral vaccination) reported clinical responses at major 2025 conferences.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/intratumoral-cancer-therapies-market?sg

Major Key Players: Pfizer Inc., Bristol Myers Squibb Company, BridgeBio Pharma, Inc., Boston Scientific Corporation.

Market Growth Drivers:

✅ Rising Global Cancer Burden
The increasing incidence of solid tumors across various age groups is a key factor driving demand for localized and targeted cancer treatment options like intratumoral therapies.

✅ Advancement in Immunotherapy and Oncolytic Viruses
Continuous progress in immuno-oncology-especially the development of oncolytic viruses, gene therapy vectors, and immune modulators-has expanded the scope of intratumoral administration for durable anti-tumor responses.

✅ Favorable Regulatory Pathways
Accelerated approval programs and orphan drug designations for novel cancer therapies have encouraged biopharmaceutical companies to focus on intratumoral delivery approaches.

✅ Growing Focus on Minimally Invasive Treatments
Intratumoral delivery minimizes systemic toxicity compared to intravenous chemotherapy, improving patient outcomes and quality of life-making it a preferred option in clinical settings.

✅ Rising Investments in Clinical Research and Trials
Increasing funding from public and private sectors for oncology research is propelling the development of innovative drug formulations, delivery devices, and combination therapies.

✅ Personalized and Combination Therapy Approaches
Integration of intratumoral therapies with immune checkpoint inhibitors, radiation, and targeted therapies has shown promising synergistic results, further enhancing adoption rates.

Segments Covered in the Intratumoral Cancer Therapies Market:

By Intratumoral Agent (Oncolytic Viruses, Adenovirus, Others)

By Cancer Type (Melanoma, Breast Cancer, Prostate Cancer, Lung Cancer, Head and Neck Cancer, Others)

By End User (Hospitals, Cancer Research Centers, Specialty Clinics, Others)

Regional Analysis for Intratumoral Cancer Therapies Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=intratumoral-cancer-therapies-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Intratumoral Cancer Therapies market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Intratumoral Cancer Therapies Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Intratumoral Cancer Therapies market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Intratumoral Cancer Therapies Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Intratumoral Cancer Therapies market?

➠ Who are the global key manufacturers of the Intratumoral Cancer Therapies Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Intratumoral Cancer Therapies market opportunities and threats faced by the vendors in the global Intratumoral Cancer Therapies Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Intratumoral Cancer Therapies market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.